BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 13.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 70,140 shares of the medical research company’s stock after selling 10,715 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Amgen were worth $29,565,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Rational Advisors Inc. increased its stake in Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after acquiring an additional 24 shares during the last quarter. Beacon Financial Advisory LLC lifted its stake in shares of Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after purchasing an additional 25 shares in the last quarter. James T. Borello RIA lifted its stake in shares of Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after purchasing an additional 25 shares in the last quarter. Sweeney & Michel LLC grew its holdings in shares of Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after purchasing an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. grew its holdings in shares of Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on AMGN. Argus increased their target price on shares of Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. Jefferies Financial Group reiterated a “hold” rating and set a $410.00 price objective on shares of Amgen in a research note on Wednesday, September 23rd. Sanford C. Bernstein increased their price objective on shares of Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 4th. Finally, Freedom Broker downgraded shares of Amgen from a “buy” rating to a “hold” rating and raised their target price for the company from $450.00 to $470.00 in a research note on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $428.62.
View Our Latest Stock Analysis on AMGN
Amgen Stock Performance
Shares of NASDAQ:AMGN opened at $435.52 on Friday. The company has a market cap of $235.58 billion, a P/E ratio of 25.26, a PEG ratio of 3.03 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The business’s 50-day simple moving average is $430.44 and its 200 day simple moving average is $383.81.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. During the same quarter in the prior year, the business earned $5.64 EPS. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 23.44 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is presently 58.47%.
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
